Opendata, web and dolomites

LAUREN

bLadder cAncer URine cEll aNalysis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "LAUREN" data sheet

The following table provides information about the project.

Coordinator
CYTOSYSTEMS LIMITED 

Organization address
address: CRUICKSHANK BUILDING CRAIBSTONE
city: ABERDEEN
postcode: AB21 9TR
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.cytosystems.com
 Total cost 3˙135˙925 €
 EC max contribution 3˙135˙925 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2018-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYTOSYSTEMS LIMITED UK (ABERDEEN) coordinator 3˙135˙925.00

Map

 Project objective

Bladder cancer is the 4th most common cancer in men and the 7th in women, with 330,000- 380,000 new cases annually worldwide or more than 150,000 in Europe and is one of the most expensive cancers to manage. Bladder cancer incidence is strongly related to age, with the highest incidence rates being in older men and women. Cystoscopy/cystoscopic biopsy remains the current gold standard diagnostic and monitoring tool. This procedure is highly invasive and expensive - costing up to €1200 per test - and has been reported to miss in the region of 25% of all bladder tumours. As an adjunct to cystoscopy, urine cytology is routinely carried out globally but its deficiencies in terms of poor cancer detection (low sensitivity) are well recognised and reported.

The overall objective of the LAUREN project is to provide a commercial non-invasive in vitro diagnostic that will significantly reduce the management cost of caring for bladder cancer patients, whilst at the same time improving patient comfort and reducing morbidity associated with current invasive procedures. The specific diagnostic is based on the MCM2 Immunofluorescence biomarker for bladder cancer cells found in urine.The scope of the project is to complete the final development, validation and regulatory activities required to prepare a novel the new diagnostic for the market.

The objectives of the project are to: PO1 Clinically validate the biomarkers including the addition of Immuno Fluorescence PO2 Complete development of and validate a single use cell collection device, PO3 Validate the cell recognition software for regulatory acceptance PO4 Validate the software of an automated slide analysis system. PO5 Prepare a complete evidence package to support obtaining a CE Mark and FDA approval for commercialisation

 Deliverables

List of deliverables.
Publicity releases Websites, patent fillings, videos etc. 2019-05-31 18:14:36

Take a look to the deliverables list in detail:  detailed list of LAUREN deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LAUREN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LAUREN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More